PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.02%
Growth of 5.02% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
4.41%
Cost growth of 4.41% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
7.85%
Growth of 7.85% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
2.70%
Margin change of 2.70% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-13.38%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
2.50%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 1.54%. Jim Chanos would check for waste.
4.12%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 1.72%. Jim Chanos would check for waste.
-7.69%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-13.71%
D&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency.
14.12%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
8.67%
Margin change of 8.67% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
30.87%
Income change of 30.87% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
24.62%
Margin change of 24.62% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-58.74%
Other expenses reduction while Medical - Pharmaceuticals median is 8.93%. Seth Klarman would investigate advantages.
14.19%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
8.73%
Margin change of 8.73% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
24.10%
Tax expense change of 24.10% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
8.00%
Income change of 8.00% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
2.84%
Margin change of 2.84% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
8.01%
EPS change of 8.01% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
8.01%
Diluted EPS change of 8.01% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.